Scisparc Ltd (SPRC) - News Archive

Innovative Collaboration in Pharmaceutical Research Sheds Light on Binge Behavior and Weight Loss Therapies In a landmark advancement within the pharmaceutical industry, the collaborative efforts of SciSparc Ltd. and Cl...

In a surprising turn of events, SciSparc Ltd. (Nasdaq: SPRC), traditionally a stalwart in the pharmaceutical sector focusing on central nervous system disorders, announced a monumental shift in its operational strategy...

In the dynamic arena of pharmaceuticals and automotive imports, few companies have managed to capture the synergy and strategic foresight quite like SciSparc Ltd. (Nasdaq: SPRC). With its dual focus a profound legacy in...

SciSparc Ltd. (Nasdaq: SPRC), an innovative clinical-stage pharmaceutical company dedicated to pioneering therapies for challenging central nervous system disorders, has been in the news for a series of significant stra...

In a strategic move that underscores its commitment to innovation and growth in the pharmaceutical sector, SciSparc Ltd. a biotechnology firm specializing in the development of advanced clinical-stage therapies, has pro...

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation IntroductionTEL AVIV, Israel, Dec. 26, 2024 - In a remarkable stride for the Israeli automotive...

Overview of Recent DevelopmentsIn a significant advancement for the treatment of Tourette Syndrome (TS), SciSparc Ltd. a clinical-stage pharmaceutical company, has received FDA approval to initiate its pivotal Phase IIb...

In a series of strategic advancements, SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company devoted to developing therapies for central nervous system disorders and rare diseases, has made sig...

The undertaking of such a pivotal study posits SciSparc Ltd at the vanguard of neurological disorder treatments, demonstrating a confluence of scientific rigour and steadfast commitment to advancing human health. The an...

SciSparc Ltd, a biopharmaceutical company focused on the development of cannabinoid-based therapies, has recently made significant progress by submitting an Investigational New Drug (IND) application to the U.S. Food an...

In a rapidly evolving economic landscape, healthcare companies are under continuous scrutiny regarding their financial strategies and investment returns. Scisparc Ltd, a company that has recently been in the spotlight f...

In this distinguished age of unparalleled innovation and relentless ambition, we find ourselves on the precipice of a significant development within the realm of pharmaceutical sciences. The venerable entity known as Sc...

Recent advancements highlight the promising potential of the unique combination of 5-Methoxy-2-Aminoindane (MEAI) with Palmitoylethanolamide (PEA) as a novel therapeutic intervention for obesity and metabolic syndrome....

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung CancerTel Aviv, Israel-based SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company, has reporte...

CSIMarket.com presents an overview of the recent developments surrounding SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on therapies for disorders and rare diseases of the cent...

SciSparc and Clearmind Medicine Collaborate on Groundbreaking Treatment for Metabolic Syndrome and ObesityIn a significant development for the pharmaceutical industry, SciSparc Ltd. and Clearmind Medicine Inc. have anno...

SciSparc Ltd., a clinical-stage pharmaceutical company specializing in treatments for disorders and rare diseases of the central nervous system, has recently announced its plans to acquire AutoMax Motors Ltd., a promine...

In recent years, the pharmaceutical industry has witnessed impressive advancements in the development of innovative therapies to combat various disorders and rare diseases. SciSparc Ltd., a pioneering clinical-stage pha...

:Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder that affects millions of children worldwide. As the prevalence of ASD continues to rise, there is an urgent need to develop effective treatments t...

SciSparc Ltd., a leading clinical-stage pharmaceutical company specializing in the development of treatments for central nervous system disorders, has recently received a Canadian patent for its innovative combination o...